1-5 of 5
Michel Delforge, MD, PhF
Close
Sort by
Journal Articles

Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma

Meletios A. Dimopoulos, MD, Antonio Palumbo, MD, Katja Weisel, MD, Enrique M. Ocio, MD PhD, Michele Cavo, MD, Paolo Corradini, MD PhD, Michel Delforge, MD PhF, Albert Oriol, MD, Hartmut Goldschmidt, MD, María Jesús Blanchard, MD, Chantal Doyen, MD, Gareth J Morgan, MD PhD, Mathew Simcock, MSc, Neil Miller, CRS, Ana Slaughter, PhD, Teresa Peluso, MBBS, Lars Sternas, MD, Mohamed H. Zaki, MD PhD, Philippe Moreau, MD
Journal: Blood
Blood (2014) 124 (21): 80.
https://doi.org/10.1182/blood.V124.21.80.80
Published: 2014
Journal Articles

Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010)

Katja Weisel, MD, Meletios A. Dimopoulos, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Antonio Palumbo, MD, Paolo Corradini, MD PhD, Michel Delforge, MD PhF, Albert Oriol, MD, Harmut Goldschmidt, MD, Concetta Conticello, MD, Angelo Vacca, MD PhD, Markus Hansson, MD PhD, Neil Miller, CRS, Teresa Peluso, MBBS, Lars Sternas, MD, Mohamed H. Zaki, MD, Philippe Moreau, MD
Journal: Blood
Blood (2014) 124 (21): 4755.
https://doi.org/10.1182/blood.V124.21.4755.4755
Published: 2014
Journal Articles

Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma

Antonio Palumbo, MD, Meletios A. Dimopoulos, MD, Katja Weisel, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Paolo Corradini, MD PhD, Michel Delforge, MD PhF, Albert Oriol, MD, Hartmut Goldschmidt, MD, Maria Jesus Blanchard, MD, Concetta Conticello, MD, Angelo Vacca, MD PhD, Markus Hansson, MD PhD, Ana Slaughter, PhD, Mathew Simcock, MSc, Jennifer Herring, MD, Teresa Peluso, MBBS, Lars Sternas, MD, Mohamed H. Zaki, MD PhD, Philippe Moreau
Journal: Blood
Blood (2014) 124 (21): 4770.
https://doi.org/10.1182/blood.V124.21.4770.4770
Published: 2014
Journal Articles

Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM)

Katja Weisel, MD, Dan T. Vogl, Michel Delforge, MD PhF, Kevin Song, Meletios Dimopoulos, Jamie Cavenagh, Cyrille Hulin, Philippe Rodon, Bertrand Arnulf, Robin Foá, MD, Albert Oriol, MD, Shien Guo, Mara Silvia Monzini, Jason Van Oostendorp, Annette Ervin-Haynes, Thierry Facon, MD
Journal: Blood
Blood (2014) 124 (21): 1326.
https://doi.org/10.1182/blood.V124.21.1326.1326
Published: 2014
Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Jesús F San Miguel, MD PhD, Rudolf Schlag, MD, Nuriet K Khuageva, MD, Meletios Athanasios Dimopoulos, MD, Ofer Shpilberg, MD, MPH, Martin Kropff, MD, Ivan Spicka, MD, PhD, Maria T Petrucci, Antonio Palumbo, MD, Olga S Samoilova, MD, Anna Dmoszynska, Kudrat M Abdulkadyrov, Prof, Michel Delforge, MD, PhF, Bin Jiang, María-Victoria Mateos, MD, PhD, Kenneth C. Anderson, MD, Dixie-Lee Esseltine, MD, FRCPC, Kevin Liu, PhD, William M Deraedt, PhD, Andrew Z Cakana, MD, FRCPath, Helgi van de Velde, MD, PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2011) 118 (21): 476.
https://doi.org/10.1182/blood.V118.21.476.476
Published: 2011